Empowering Recovery
Stimulate Bone Healing and Reduce Risk of Infection
Welcome to Richard Cornell, where innovation meets healthcare. Our ground-breaking biotechnology is designed to accelerate bone healing while combating infections, all without the need for antibiotics. Join us in revolutionising the future of medicine.
Our Technology
Innovative Approach
Our patented biotechnology stimulates rapid bone healing while addressing infections without relying on antibiotics. Our technology is effective against antibiotic-resistant bacteria. We are pioneering a new era in healthcare, ensuring patients receive the best care possible and reducing treatment costs.
With a focus on patient safety and effective healing, our technology offers a promising alternative to traditional bone healing methods. Join us in embracing the future of healthcare with Richard Cornell
Who We Are
Richard Cornell is a visionary biotech startup dedicated to transforming bone healing. Our mission is to develop innovative solutions that revolutionise anti-infective musculoskeletal treatments, reducing healthcare costs, and offering patients a faster and safer recovery process.
Antimicrobial Resistance
Global
By 2050 if not addressed Antibiotic Resistance could lead to:
10m Deaths
Costing
£66 trillion
Europe
25,000
people die each year from hospital infections
by 5 Key
resistant bacteria
How We Change the World
Innovation
Our highly innovative biomaterials have more than one function. They have been designed from the beginning for these purposes.
This gives us control over the stimulation of bone healing, antimicrobial function and through our exciting controlled-release technology we can pace these functions.
Excitingly, our technology is effective against antibiotic-resistant bacteria. There are early studies that show that our approach is also unlikely to lead to bacterial resistance.
We spearhead a consortium of experts and researchers from across industry and academia. We can take our technology ideas from invention to the clinical and market quicker and more effectively.
Raising Awareness
Our products will be a key musculoskeletal treatment as current antibiotics become increasingly ineffective. Antimicrobial resistance will herald the arrival of untreatable infections and the prospect of treatment involving bone healing becoming almost impossible.
Richard Cornell is publicising this issue and helping kick-start the identification of the next wave of antimicrobial treatments. We speak with drug companies, investors, public bodies, medical charities, government organisations, patients and members of the lay public.
​
We believe that together we will solve this urgent challenge to the global community.
Engagement
Despite current antibiotics becoming increasingly ineffective, many major pharmaceutical companies abandoned research into new antibiotics decades ago for commercial and clinical reasons.
Laboratory studies show that products like ours are effective against key bacteria, even if they are multiply-resistant to current antibiotics.
With the current threat of potentially untreatable infections, the identification of new treatments such as ours to overcome antimicrobial resistance, is not only timely but are critical to offering continued therapies.
​
Richard Cornell is committed to being in the vanguard of these new therapies, with commitments to engagement across society from patients to politicians.
